Skip to main content
. 2024 Nov 15;17(11):429–438. doi: 10.62347/XOPN6908

Figure 4.

Figure 4

Combination of PARPi with cGAS inhibition exhibits synergetic effects to overcome PARPi resistance. A. qRT-PCR analysis of IFNB1 and CXCL10 mRNA in OVCAR-8 cells treated with Olaparib or/and cGAS inhibitor RU.521. B. ELISA quantification of IFN-β secretion in OVCAR-8 cells treated with Olaparib or/and RU.521. C. Immunoblot analysis of total and p-TBK1, total and p-IRF3 in OVCAR-8 cells, followed by treatment Olaparib or/and RU.521. D. Densitometric analysis of p-TBK1 and p-IRF3 protein expression levels was quantitated by “ImageJ” software. E. qRT-PCR analysis of IL6 mRNA in OVCAR-8 cells treated with Olaparib or/and cGAS inhibitor RU.521. F. CCK-8 detection of Olaparib sensitivity in OVCAR-8 or SK-OV-3 cells treated with DMSO or cGAS inhibitor RU.521. A, B, D-G. Data are the mean ± SD; one-way ANOVA with Dunnett’s multiple comparisons test; *P < 0.033, **P < 0.002 and ***P < 0.001.